Ironwood Pharmaceuticals Inc. (IRWD)
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
What's in Store for These 5 Medical Companies This Earnings Season?
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?
IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.
